Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, 430030 Wuhan, China.
Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, 430030 Wuhan, China.
Biomed Res Int. 2022 Oct 10;2022:5432806. doi: 10.1155/2022/5432806. eCollection 2022.
TP53 mutation is a common mutation gene in uterine corpus endometrial carcinoma (UCEC), and the TP53 signaling pathway plays an essential role in the tumorigenesis, progression, and immune infiltration in UCEC. We aimed to discover TP53 pathway-related lncRNAs in UCEC. . 528 UCEC patients with 587 transcriptional profiles were enrolled in this study. We first investigated the differential status of TP53 signaling pathway between tumor and normal tissues by GSEA analysis, then identified TP53 pathway-related lncRNAs, accordingly establishing a nine TP53 pathway related to the lncRNA signature in the training set and verified this signature in the test set. Besides, the interaction network was constructed; the immune infiltration, drug response to cisplatin and paclitaxel, and mutation atlas were investigated. Finally, we performed a subgroup analysis to check the universality of this signature.
A nine TP53 pathway-related lncRNA prognostic signature was constructed and verified superior accuracy in predicting the overall survival of UCEC patients. Besides, high-risk patients showed a poor prognosis, but they were more sensitive to the cisplatin and paclitaxel. Notably, M2 macrophages were higher infiltrated in high-risk patients, and TP53 showed a significantly higher mutation in high-risk patients than low-risk patients.
We constructed and verified a nine TP53 pathway-related lncRNA prognostic signature in UCEC, which also contributes to the decision-making of the chemotherapy.
TP53 突变是子宫体子宫内膜癌(UCEC)中常见的突变基因,TP53 信号通路在 UCEC 的肿瘤发生、进展和免疫浸润中起着至关重要的作用。我们旨在发现 UCEC 中与 TP53 通路相关的 lncRNA。本研究纳入了 528 例 UCEC 患者和 587 个转录谱。我们首先通过 GSEA 分析研究了 TP53 信号通路在肿瘤和正常组织之间的差异状态,然后鉴定了与 TP53 通路相关的 lncRNA,相应地在训练集中建立了一个与 9 个 TP53 通路相关的 lncRNA 特征,并在测试集中验证了该特征。此外,构建了互作网络;研究了免疫浸润、顺铂和紫杉醇的药物反应以及突变图谱。最后,我们进行了亚组分析,以检查该特征的普遍性。
构建并验证了一个与 9 个 TP53 通路相关的 lncRNA 预后签名,可更准确地预测 UCEC 患者的总生存率。此外,高危患者预后较差,但对顺铂和紫杉醇更敏感。值得注意的是,高危患者中 M2 巨噬细胞浸润较高,且高危患者中 TP53 的突变明显高于低危患者。
我们构建并验证了 UCEC 中与 9 个 TP53 通路相关的 lncRNA 预后签名,这也有助于化疗决策。